Interferons in Traumatic Brain and Spinal Cord Injury: Current Evidence for Translational Application
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
This review article provides a general perspective of the experimental and clinical work surrounding the role of type-I, type-II, and type-III interferons (IFNs) in the pathophysiology of brain and spinal cord injury. Since IFNs are themselves well-known therapeutic targets (as well as pharmacological agents), and anti-IFNs monoclonal antibodies are being tested in clinical trials, it is timely to review the basis for the repurposing of these agents for the treatment of brain and spinal cord traumatic injury. Experimental evidence suggests that IFN-α may play a detrimental role in brain trauma, enhancing the pro-inflammatory response while keeping in check astrocyte proliferation; converging evidence from genetic models and neutralization by monoclonal antibodies suggests that limiting IFN-α actions in acute trauma may be a suitable therapeutic strategy. Effects of IFN-β administration in spinal cord and brain trauma have been reported but remain unclear or limited in effect. Despite the involvement in the inflammatory response, the role of IFN-γ remains controversial: although IFN-γ appears to improve the outcome of traumatic spinal cord injury, genetic models have produced either beneficial or detrimental results. IFNs may display opposing actions on the injured CNS relative to the concentration at which they are released and strictly dependent on whether the IFN or their receptors are targeted either via administration of neutralizing antibodies or through genetic deletion of either the mediator or its receptor. To date, IFN-α appears to most promising target for drug repurposing, and monoclonal antibodies anti IFN-α or its receptor may find appropriate use in the treatment of acute brain or spinal cord injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Type I interferons in infectious disease
McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780 · cited 2×
“A third family (type-III) of IFNs has been more recently described and includes IFN-λ1, IFN-λ2, IFN-λ3 (also known as IL-29, IL-28A, and IL-28B, respectively) and IFN-λ4 (3, 4).”
BackgroundRothhammer, V., Mascanfroni, I. D., Bunse, L., Takenaka, M. C., Kenison, J. E., Mayo, L., Chao, C.-C., Patel, B., Yan, R., Blain, M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4106 · Cited by 1,559
Blockade of chronic type I interferon signaling to control persistent LCMV infection
Wilson, E. B., Yamada, D. H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., Aronow, B. J., Karp, C. L., & Brooks, D. G. (2013) · Science · doi:10.1126/science.1235208 · Cited by 709 · cited 1×
“In a different setting involving the comparison of acute and chronic LCMV infection, suppression of type-I IFN signaling by deletion of the Ifnar gene (which encodes the IFN receptor shared by all type-I IFNs) ameliorates the clearing of the LCMV and the resolution of the inflammatory response through a mechanism requ…”
BackgroundGAS Elements: A Few Nucleotides with a Major Impact on Cytokine-Induced Gene Expression
DECKER, T., KOVARIK, P., & MEINKE, A. (1997) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1997.17.121 · Cited by 437
IFN-γ-dependent activation of the brain’s choroid plexus for CNS immune surveillance and repair
Kunis, G., Baruch, K., Rosenzweig, N., Kertser, A., Miller, O., Berkutzki, T., & Schwartz, M. (2013) · Brain · doi:10.1093/brain/awt259 · Cited by 321
In Situ Detection of Inflammatory Mediators in Post Mortem Human Brain Tissue after Traumatic Injury
Frugier, T., Morganti-Kossmann, M. C., O'Reilly, D., & McLean, C. A. (2010) · Journal of Neurotrauma · doi:10.1089/neu.2009.1120 · Cited by 278 · cited 1×
“Interestingly, the area of the cortex used for cytokine analysis also presented astrogliosis and macrophage activation located in proximity to axonal pathology, implying a direct link between cellular and humoral inflammation (40).”
Lack of Neuronal IFN-β-IFNAR Causes Lewy Body- and Parkinson’s Disease-like Dementia
Ejlerskov, P., Hultberg, J. G., Wang, J., Carlsson, R., Ambjørn, M., Kuss, M., Liu, Y., Porcu, G., Kolkova, K., Friis Rundsten, C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.069 · Cited by 211 · cited 1×
“Conversely, deletion of the IFN-β gene in dopaminergic cells results in the appearance of Parkinson’s Disease-like pathological features, in particular synuclein aggregates, as a consequence of impaired autophagy (19).”
BackgroundType-1 interferon signaling mediates neuro-inflammatory events in models of Alzheimer’s disease
Taylor, J. M., Minter, M. R., Newman, A. G., Zhang, M., Adlard, P. A., & Crack, P. J. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.089 · Cited by 145 · cited 1×
“Type-I IFNs have been shown to be involved in the pathogenic cascades of neurodegenerative diseases, whereby IFN-α contributes to the appearance of amyloid-related cognitive deficits in animal models of Alzheimer’s Disease (18) and deletion of the Ifnar gene has been shown to ameliorate cognitive deficits and attenuat…”
BackgroundInduction of miR-155 after Brain Injury Promotes Type 1 Interferon and has a Neuroprotective Effect
Harrison, E. B., Emanuel, K., Lamberty, B. G., Morsey, B. M., Li, M., Kelso, M. L., Yelamanchili, S. V., & Fox, H. S. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00228 · Cited by 48 · cited 1×
“In contrast, microglia activation was increased by 25% in miR-155-KO mice together with a reduction in neuronal survival (37).”
BackgroundN-acetyl-cysteine prevents toxic oxidative effects induced by IFN-α in human neurons
Alboni, S., Gibellini, L., Montanari, C., Benatti, C., Benatti, S., Tascedda, F., Brunello, N., Cossarizza, A., & Pariante, C. M. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000266 · Cited by 35
Cited by
Decoding the Transcriptional Response to Ischemic Stroke in Young and Aged Mouse Brain
Androvic, P., Kirdajova, D., Tureckova, J., Zucha, D., Rohlova, E., Abaffy, P., Kriska, J., Valny, M., Anderova, M., Kubista, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107777 · Cited by 118
Monzón-Sandoval, J., Burlacu, E., Agarwal, D., Handel, A. E., Wei, L., Davis, J., Cowley, S. A., Cader, M. Z., & Webber, C. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049349 · Cited by 18
Metadata
- Authors
- Roselli, F., Chandrasekar, A., & Morganti-Kossmann, M. C.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2018-06-19
- Volume
- 9
- Pages
- 458-458
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W2807219700
- Cited by
- 60
- References
- 10
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interferons in Traumatic Brain and Spinal Cord Injury: Current Evidence for Translational Application. https://app.cochat.ai/papers/10.3389/fneur.2018.00458
- The paper
- Roselli, F., Chandrasekar, A., & Morganti-Kossmann, M. C. (2018). Interferons in Traumatic Brain and Spinal Cord Injury: Current Evidence for Translational Application. Frontiers in Neurology. https://doi.org/10.3389/fneur.2018.00458
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.